Ludwig Merker - Concepedia

Author

Ludwig Merker

Dorma (Germany)

Also Known As

L Merker, L. Merker, Ludwig Merker, Michael Roden

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Dorma (Germany)Boehringer Ingelheim (Germany)Boehringer Ingelheim (Denmark)University of Tübingen Boehringer Ingelheim (France)

About

Ludwig Merker is an author at Dorma (Germany) specializing in diabetes, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	585
2	Diabetes	3	3	585
3	Pharmacology	2	2	184
4	Pharmacotherapy	2	2	184
5	Metabolic Syndrome	1	1	75

Ludwig Merker

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial Simon Heller, John B. Buse, Miles Fisher, The Lancet Type 1Diabetes ManagementInsulin DegludecDiabetesInsulin Management	2012	401
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial Hans‐Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Diabetes Care	2014	383
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes Hans‐Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Diabetes Care	2013	368
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus Christopher S. Kovács, Veeraswamy Seshiah, Ludwig Merker, Clinical Therapeutics Diabetes ManagementMedicineInsulin ManagementDiabetesType 2	2015	109
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN<sup>®</sup> Basal–Bolus Type 1): 2‐year results of a randomized clinical trial Bruce W. Bode, John B. Buse, Miles Fisher, Diabetic Medicine	2013	94
Empagliflozin as add‐on to metformin in people with Type 2 diabetes Ludwig Merker, H.-U. Häring, Anita Vedel Christiansen, Diabetic Medicine	2015	75
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes Hans-Ulrich Haering, Ludwig Merker, Anita Vedel Christiansen, Diabetes Research and Clinical Practice Metabolic SyndromeDiabetes ManagementMedicineInsulin ManagementDiabetes	2015	75

Page 1